Ardsley, New York-based biopharmaceutical firm Acorda Therapeutics revealed new information derived from clinical and preclinical studies of tozadenant at the recent 2017 International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Vancouver, British Columbia. Read More »
Purdue Pharma's Colace product line and Senokot tablets will now come with new packaging. Read More »
Do television ads by plaintiffs' lawyer firms hawking lawsuits over prescription drugs cause patients to cease taking their prescribed prescriptions? Read More »
Commencing a Phase 3b trial of daily oral medication ALKS 5461, Alkermes PLC will assess the treatment’s feasibility and safety for major depressive disorder patients with insufficient prior results obtained from other drugs. Read More »
The Health Affairs Blog, a vehicle for commentary on health policy and issues affecting the health care industry, recently release an article on surprise medical bills. Read More »
MD Logistics, a third-party logistics company that works with pharmaceutical companies, will expand its Indiana operations, creating 50 new jobs in the process. Read More »
Merck has paused enrollment in two Keytruda clinical trials. Read More »
A new study published in the Journal of the American Medical Association finds that doctors are influenced by gifts and their relationships with drug company representatives. Read More »
Drug Channels, a website providing expert insights on pharmaceutical economics and the drug distribution system, recently commented on a new report from the Centers for Medicare & Medicaid Services, titled “Medicare Part D – Direct and Indirect Remuneration.” Read More »
Sandoz has introduced the authorized generic version of Alcon Research Ltd.'s Pataday, an olopatadine hydrochloride ophthalmic solution. Read More »
Omnicell Inc. announced an agreement with CompleteRX to develop a medication distribution model for the Commonwealth of Massachusetts State Office of Pharmacy Services. Read More »
Global generic pharmaceutical giant Teva recently released its generic version of Zetia (ezetimibe) in 10mg tablets to address total and low-density lipoprotein (LDL) blood cholesterol levels for U.S. patients, company officials announced from Jerusalem headquarters. Read More »
After documenting recent product abuse, the U.S. Food and Drug Administration asked Endo Pharmaceuticals to voluntarily remove its reformulated Opana ER (oxymorphone hydrochloride) opioid medication from circulation, stating that risks may now outnumber benefits. Read More »
Alkermes PLC’s Aristada (aripiprazole lauroxil) injectable medication has won approval from the U.S. Food and Drug Administration as an extended-release injectable suspension to treat schizophrenia. Read More »
Sanofi Pasteur's Quadracel vaccine has been approved by the U.S. Food and Drug Administration to protect children between the ages of 4 and 6 against diphtheria, tetanus, pertussis and poliomyelitis. Read More »
Astellas, a global pharmaceutical corporation with U.S. headquarters in Northbrook, Illinois, and biotechnology company Seattle Genetics recently publicized findings on their enfortumab vedotin (ASG-22ME) treatment for a type of cancer commonly manifesting in the bladder. Read More »
ReachBio Research Labs recently announced that it launched cellPrism, a drug development platform designed to deliver a spectrum of customized in-vitro assays to biotechnology and pharmaceutical companies. Read More »
OneOme, the company behind the OneOme RightMed pharmacogenomics test, recently delivered a statement about how DNA has the power to minimize medication trial and error and help people with heart conditions improve their cardiovascular treatments. Read More »
Enanta Pharmaceuticals Inc.'s New Drug Application (NDA) for its pan-genotypic regimen of glecaprevir/pibrentasvir (G/P), developed in conjunction with AbbVie, has been accepted by the U.S Food and Drug Administration. Read More »
The American Pharmacists Association (APA) recently announced that new research shows adding 24 months of antiandrogen therapy with daily bicalutamide to salvage radiation therapy led to an increase in survival rates and for patients with recurrent prostate cancer. Read More »
Alerts Sign-up
